 Connection
Bryan Haugen to Thyroxine
This is a "connection" page, showing publications Bryan Haugen has written about Thyroxine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.092 |
|
|
|
-
Haugen B, Hennessey JV, Leonard W. Patient Information Page. Medicines for hypothyroidism. J Clin Endocrinol Metab. 2011 Aug; 96(8):1, 2.
Score: 0.362
-
Barrio M, Raeburn CD, McIntyre R, Albuja-Cruz M, Haugen BR, Pozdeyev N. Computer-Assisted Levothyroxine Dose Selection for the Treatment of Postoperative Hypothyroidism. Thyroid. 2023 05; 33(5):547-555.
Score: 0.204
-
Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM, Haugen BR. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Mol Cell Endocrinol. 2011 Jun 06; 339(1-2):1-6.
Score: 0.089
-
Hennessey JV, Malabanan AO, Haugen BR, Levy EG. Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr Pract. 2010 May-Jun; 16(3):357-70.
Score: 0.083
-
Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30.
Score: 0.065
-
H?nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54.
Score: 0.063
-
Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology. 2006 Mar; 147(3):1438-51.
Score: 0.061
-
Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest. 2000 Jul; 106(1):73-9.
Score: 0.042
-
Haugen BR. Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):139-45.
Score: 0.041
-
Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998 Sep; 8(9):737-44.
Score: 0.037
-
Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocr Pract. 2017 May; 23(5):566-575.
Score: 0.033
-
McDermott MT, Haugen BR, Lezotte DC, Seggelke S, Ridgway EC. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid. 2001 Aug; 11(8):757-64.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|